Article
Oncology
Xiaoqing Fan, Junqi Fan, Haoran Yang, Chenggang Zhao, Wanxiang Niu, Zhiyou Fang, Xueran Chen
Summary: This study identified a mutation in isocitrate dehydrogenase 1 that suppresses the TGF-beta signaling pathway, while highlighting the roles of Smad3 and EP300 in promoting expression of mesenchymal markers in the mesenchymal subtype of GBM. Smad3 and hypoxia-inducible factor 1-alpha may be crucial molecular targets for treating glioma due to their coordination in cancer stem cell biology.
Article
Multidisciplinary Sciences
Roberta Zappasodi, Inna Serganova, Ivan J. Cohen, Masatomo Maeda, Masahiro Shindo, Yasin Senbabaoglu, McLane J. Watson, Avigdor Leftin, Rachana Maniyar, Svena Verma, Matthew Lubin, Myat Ko, Mayuresh M. Mane, Hong Zhong, Cailian Liu, Arnab Ghosh, Mohsen Abu-Akeel, Ellen Ackerstaff, Jason A. Koutcher, Ping-Chih Ho, Greg M. Delgoffe, Ronald Blasberg, Jedd D. Wolchok, Taha Merghoub
Summary: By blocking CTLA-4, metabolic fitness and immune cell infiltration in tumours, especially those with low glycolytic activity, can be enhanced. This improves therapeutic outcomes, particularly in tumours with defective glycolysis, by destabilizing T-reg cells and promoting the activity of tumour-specific CD8(+) T cells.
Article
Oncology
Justin Joseph, Capucine R. Magaut, Simon Storevik, Luiz H. Geraldo, Thomas Mathivet, Md Abdul Latif, Justine Rudewicz, Joris Guyon, Matteo Gambaretti, Frida Haukas, Amalie Trones, Lars A. Romo Ystaas, Jubayer A. Hossain, Sandra Ninzima, Sylvain Cuvellier, Wenjing Zhou, Tushar Tomar, Barbara Klink, Lalit Rane, Bronwyn K. Irving, Joanne Marrison, Peter O'Toole, Heiko Wurdak, Jian Wang, Zhang Di, Even Birkeland, Frode S. Berven, Frank Winkler, Frank A. E. Kruyt, Andreas Bikfalvi, Rolf Bjerkvig, Thomas Daubon, Hrvoje Miletic
Summary: Analysis of TCGA data revealed a high activation of the TGF-beta pathway in GBMs compared to oligodendroglial tumors. Stimulation of GBM cell lines with TGF-beta 1 enhanced MT formation and communication via calcium signaling, while inhibition of the TGF-beta pathway significantly reduced MT formation and invasion. Downstream of TGF-beta, thrombospondin 1 (TSP1) was identified as a potential mediator of MT formation in GBM, which was upregulated upon TGF-beta stimulation and inhibited MT formation when knocked down in vitro and in vivo.
Review
Pharmacology & Pharmacy
Yuqian Feng, Huimin Jin, Kaibo Guo, Yuying Xiang, Yiting Zhang, Wurong Du, Minhe Shen, Shanming Ruan
Summary: The study supports the efficacy of combination therapy with immune checkpoint inhibitors (ICIs) in cancer treatment, especially showing longer PFS in patients with high PD-L1 expression. More high-quality clinical randomized controlled trials are needed in the future to confirm these findings, as the number of included trials was limited.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Adriana Amaro, Francesco Reggiani, Daniela Fenoglio, Rosaria Gangemi, Anna Tosi, Alessia Parodi, Barbara Banelli, Valentina Rigo, Luca Mastracci, Federica Grillo, Alessandra Cereghetti, Aizhan Tastanova, Adhideb Ghosh, Fabio Sallustio, Laura Emionite, Antonio Daga, Tiziana Altosole, Gilberto Filaci, Antonio Rosato, Mitchell Levesque, Michele Maio, Ulrich Pfeffer, Michela Croce
Summary: The addition of Guadecitabine, an epigenetic drug, to immune checkpoint blockade therapy has shown promising results in treating malignant melanoma. It enhances the efficacy of the therapy by increasing immune cell activity and reducing tumor growth and metastasis.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Immunology
Parviz Azimnasab-Sorkhabi, Maryam Soltani-Asl, Tulio Teruo Yoshinaga, Cristina de Oliveira Massoco, Jose Roberto Kfoury Junior
Summary: Cancer is classified into metabolic and/or genetic disorders, and the tryptophan catabolism pathway plays a vital role in different cancer types. This study focused on the interaction between the CTLA-4 receptor and IDO enzyme, and found that blocking IDO reduces the efficiency of anti-CTLA-4 antibody on cancer cell migration and clonogenic abilities. Further investigation into the molecular interaction between CTLA-4 and IDO could improve the efficacy of CTLA-4 immunotherapy.
IMMUNOLOGIC RESEARCH
(2023)
Article
Pharmacology & Pharmacy
En-ming Tian, Ming-cheng Yu, Mei Feng, Li-xue Lu, Cheng-long Liu, Li-an Shen, Yong-hui Wang, Qiong Xie, Di Zhu
Summary: The study demonstrates that JG-1, a potent and selective small-molecule ROR gamma t agonist, promotes Th17 cells differentiation and inhibits regulatory T cells, leading to robust tumor growth inhibition in multiple syngeneic models. JG-1 also shows a synergistic effect with CTLA-4 antibody, indicating its potential as a promising therapeutic agent for tumor immunity.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Cell Biology
Zhenhua Deng, Jinren Zhou, Xiaoxin Mu, Jian Gu, Xiangyu Li, Qing Shao, Jinyang Li, Chao Yang, Guoyong Han, Jie Zhao, Yongxiang Xia
Summary: The co-infusion of hAMSC and Treg was found to prevent liver fibrosis, with Treg improving the function of hAMSC by regulating the TGF-β-IDO signaling. This provides a promising approach for treating liver cirrhosis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Pathology
Ilaria Porcellato, Chiara Brachelente, Katia Cappelli, Laura Menchetti, Serenella Silvestri, Monica Sforna, Samanta Mecocci, Selina Iussich, Leonardo Leonardi, Luca Mechelli
Summary: The expression of immune suppression markers in canine melanocytic tumors is associated with increased risk of death and poorer prognosis, suggesting a potential role in immunotherapy and prognosis prediction for canine melanoma.
VETERINARY PATHOLOGY
(2021)
Article
Cell Biology
Isabel Burghardt, Judith Johanna Schroeder, Tobias Weiss, Dorothee Gramatzki, Michael Weller
Summary: The members of the TGF-beta superfamily and T beta RIII play crucial roles in regulating malignant features of glioblastoma by promoting invasiveness, angiogenesis, immunosuppression, and maintaining stem cell-like properties. The study revealed that sT beta RIII is expressed in glioblastoma tissue, potentially enhancing the activity of the TGF-beta pathway in the tumor.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Review
Oncology
Shuang Huang, Gang Zheng, Kai Yang
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in malignant solid tumors. The results showed that the addition of CTLA-4 inhibitors did not significantly improve overall response rate and survival outcomes. However, there was an increased risk of grade 3-4 adverse events with the combination therapy. More large-scale and multicenter randomized controlled trials are needed to obtain more reliable results.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Immunology
Woo-Sung Lee, Kyung-Ho Nam, Jong Hoon Kim, Won-Ju Kim, Jeong Eun Kim, Eui-Cheol Shin, Gil-Ran Kim, Je-Min Choi
Summary: This study investigated the effects of a cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling peptide (dNP2-ctCTLA-4) in psoriasis. The results showed that treatment with dNP2-ctCTLA-4 peptide reduced psoriatic skin inflammation, increased Treg cell proportion, and decreased IL-17 production by T cells, indicating a potential role in modulating psoriatic skin disease.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Christopher Larson, Bryan Oronsky, Tony Reid
Summary: Monoclonal antibodies targeting PD-1/PD-L1 and CTLA-4 have revolutionized the treatment of various cancers. However, resistance to these inhibitors is a major challenge. This study evaluated a combination therapy using an oncolytic adenovirus and PD-L1 blockade, which showed potential in reversing PD-L1 resistance.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Shasha Liu, Chaoqi Zhang, Boqiao Wang, Huanyu Zhang, Guohui Qin, Congcong Li, Ling Cao, Qun Gao, Yu Ping, Kai Zhang, Jingyao Lian, Qitai Zhao, Dan Wang, Zhen Zhang, Xuan Zhao, Li Yang, Lan Huang, Bo Yang, Yi Zhang
Summary: The intense infiltration of regulatory T cells (Tregs) facilitates the qualities of glioma stem cells (GSCs) through TGF-beta secretion and NF-κB-IL6-STAT3 signaling pathway, leading to increased cancer stemness and tumorigenic potential. Blocking the IL6 receptor can mitigate the promotion effect of Tregs on glioma growth, and the expression levels of CD133, IL6, and TGF-beta could serve as prognosis markers for glioma patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L. Cleary, Mimoza Boden, Linda Martensson, Johann Foloppe, Ingrid Teige, Eric Quemeneur, Bjorn Frendeus
Summary: This study demonstrates a highly effective and safe strategy to target CTLA-4 using a vectorized alpha CTLA-4 with strong Treg-depleting and checkpoint-blocking properties. This approach shows promising results in enhancing anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Tanwir Hasan, Seamus P. Caragher, Jack M. Shireman, Cheol H. Park, Fatemeh Atashi, Shivani Baisiwala, Gina Lee, Donna Guo, Jennifer Y. Wang, Mahua Dey, Meijing Wu, Maciej S. Lesniak, Craig M. Horbinski, C. David James, Atique U. Ahmed
CELL DEATH & DISEASE
(2019)
Review
Biochemistry & Molecular Biology
Wei X. Huff, Jae Hyun Kwon, Mario Henriquez, Kaleigh Fetcko, Mahua Dey
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Review
Behavioral Sciences
Sebastian Otto-Meyer, Jan Lumibao, Eugene Kim, Erik Ladomersky, Lijie Zhai, Kristen L. Lauing, Denise M. Scholtens, Frank Penedo, Christina Amidei, Rimas Lukas, Derek A. Wainwright
CURRENT OPINION IN BEHAVIORAL SCIENCES
(2019)
Article
Biochemical Research Methods
Hannah Marie Brown, Fan Pu, Mahua Dey, James Miller, Mitesh V. Shah, Scott A. Shapiro, Zheng Ouyang, Aaron A. Cohen-Gadol, R. Graham Cooks
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2019)
Article
Oncology
Michael S. Oh, Alex Guzner, Derek A. Wainwright, Nisha A. Mohindra, Young K. Chae, Amir Behdad, Victoria M. Villaflor
Summary: This study found that the use of beta blockers in lung cancer patients undergoing immunotherapy was associated with improved progression free survival. Stress signaling in anti-cancer immunity was highlighted, suggesting that this treatment strategy should be further explored in prospective studies.
CLINICAL LUNG CANCER
(2021)
Article
Pharmacology & Pharmacy
Meejeon Roh, Derek A. Wainwright, Jennifer D. Wu, Yong Wan, Bin Zhang
CURRENT OPINION IN PHARMACOLOGY
(2020)
Article
Neurosciences
Teresa P. Easwaran, Nicola Lancki, Mario Henriquez, Alexander O. Vortmeyer, Nicholas M. Barbaro, Denise M. Scholtens, Atique U. Ahmed, Mahua Dey
Summary: This study investigated the association between molecular classification of gliomas and seizure presentation as well as post-operative seizure control. It found that the presence of IDH mutation is associated with seizures at presentation, while IDH-mutant tumors are associated with worse post-operative seizure outcomes.
NEUROMOLECULAR MEDICINE
(2021)
Review
Clinical Neurology
D. K. Mitchell, H. J. Kwon, P. A. Kubica, W. X. Huff, R. O'Regan, M. Dey
Summary: Brain metastasis is the most common malignant intracranial neoplasm in adults, with an increasing incidence due to improved surveillance, effective systemic therapy, and an aging population. Timely and accurate diagnosis is crucial for improving long-term outcomes. Treatment approaches should be based on the type and molecular profile of the primary tumor, as well as the size, number, and location of metastatic lesions.
Article
Biology
Payal Dhar, Fahmin Basher, Zhe Ji, Lei Huang, Si Qin, Derek A. Wainwright, Jerid Robinson, Shaye Hagler, Jing Zhou, Sean MacKay, Jennifer D. Wu
Summary: Research shows that tumor-derived NKG2D ligand soluble MIC can reprogram NK cells and provides a rationale for targeting sMIC to enhance the efficacy of current NK cell-based cancer immunotherapies.
COMMUNICATIONS BIOLOGY
(2021)
Article
Oncology
Wenjing Xuan, Wen-Hao Hsu, Fatima Khan, Madeline Dunterman, Lizhi Pang, Derek A. Wainwright, Atique U. Ahmed, Amy B. Heimberger, Maciej S. Lesniak, Peiwen Chen
CANCER IMMUNOLOGY RESEARCH
(2022)
Review
Health Care Sciences & Services
Sudarshawn Damodharan, Montserrat Lara-Velazquez, Brooke Carmen Williamsen, Jeffrey Helgager, Mahua Dey
Summary: Diffuse intrinsic pontine glioma (DIPG) is a type of brainstem tumor that occurs primarily in children and is characterized by high infiltrative capacity and multiple genetic mutations. Advances in molecular understanding, including the categorization of tumors with the H3 K27M mutation and the development of treatment options, have improved our knowledge of this disease.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Oncology
Toni Q. Cao, Derek A. Wainwright, Catalina Lee-Chang, Jason Miska, Adam M. Sonabend, Amy B. Heimberger, Rimas Lukas
Summary: Despite current standard treatments, prognosis for glioblastoma patients remains poor. Immunotherapy, which harnesses the patient's immune system, has shown success in non-central nervous system cancers but lacks efficacy for glioblastoma. Factors impacting immunotherapy efficacy for glioblastoma have become a new focus of research.
Article
Cell Biology
Jack M. Shireman, Nikita Gonugunta, Lei Zhao, Akshita Pattnaik, Emily Distler, Skyler Her, Xiaohu Wang, Rahul Das, Jaques Galipeau, Mahua Dey
Summary: Age-related immune dysfunctions have close connections with pathologies like cancers and lack of vaccine efficacy among the elderly. An engineered fusokine, GIFT-7, has the potential to reverse aging-related lymphoid organ atrophy. In experiments using aged mouse models of glioblastoma, peripheral vaccination with GIFT-7TVax resulted in thymic regeneration, long-term antitumor immunity, increased pro-inflammatory cytokines, enhanced T-cell trafficking to the brain, and robust T-cell formation.
Review
Oncology
Jack M. Shireman, Simon Ammanuel, Jens C. Eickhoff, Mahua Dey
Summary: This study reveals significant differences in immunobiology between males and females, which also affect the overall response to immunotherapy in GBM treatment.
NEURO-ONCOLOGY ADVANCES
(2022)
Article
Oncology
Rimas Lukas, Derek A. Wainwright, Erik Ladomersky, Sean Sachdev, Adam M. Sonabend, Roger Stupp